Becton, dickinson and companyBDX.US Overview
BDX Overall Performance
BDX AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
BDX Current Performance
0.78%
Becton, dickinson and company
0.67%
Avg of Sector
0.51%
S&P500
BDX Key Information
BDX Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
BDX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
BDX Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Price of BDX
BDX FAQ
When is BDX's latest earnings report released?
The most recent financial report for Becton, dickinson and company (BDX) covers the period of 2025Q3 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BDX's short-term business performance and financial health. For the latest updates on BDX's earnings releases, visit this page regularly.
Where does BDX fall in the P/E River chart?
According to historical valuation range analysis, Becton, dickinson and company (BDX)'s current price-to-earnings (P/E) ratio is 33.94, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of BDX?
According to the latest financial report, Becton, dickinson and company (BDX) reported an Operating Profit of 882M with an Operating Margin of 16.01% this period, representing a growth of 46.51% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is BDX's revenue growth?
In the latest financial report, Becton, dickinson and company (BDX) announced revenue of 5.51B, with a Year-Over-Year growth rate of 10.4%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does BDX have?
As of the end of the reporting period, Becton, dickinson and company (BDX) had total debt of 19.34B, with a debt ratio of 0.35. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does BDX have?
At the end of the period, Becton, dickinson and company (BDX) held Total Cash and Cash Equivalents of 797M, accounting for 0.01 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does BDX go with three margins increasing?
In the latest report, Becton, dickinson and company (BDX) achieved the “three margins increasing” benchmark, with a gross margin of 47.8%%, operating margin of 16.01%%, and net margin of 10.4%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess BDX's profit trajectory and future growth potential.
Is BDX's EPS continuing to grow?
According to the past four quarterly reports, Becton, dickinson and company (BDX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of BDX?
Becton, dickinson and company (BDX)'s Free Cash Flow (FCF) for the period is 1.05B, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 3.78% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of BDX?
The latest valuation data shows Becton, dickinson and company (BDX) has a Price-To-Earnings (PE) ratio of 33.94 and a Price/Earnings-To-Growth (PEG) ratio of 0.26. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.